Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

Table 1 Efficacy data summary (from the RATIFY clinical trial cut-off)

	MIDO-treated patients	SOC-treated patients
Overall survival (non-censored), %	46	42
Event-free survival, %	27	18
Stem cell therapy received during trial, %	59	55

ISSN: 1478-7547